Amgen Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
354 / 1361
Position in country
6223 / 14179
Return on Assets, %
7.9
-40.3
Net income margin, %
9.3
-180
EBITDA margin, %
32.5
-168.2
Debt to Equity, %
1036.7
3.2
Intangible assets and goodwill, %
52.7
0.2
Revenue CAGR 3Y, %
3.5
12.5
Total Equity change 1Y, %
70.2
-9
Revenue Y, % chg
7
0
P/E
21.3
31
P/BV
22.9
1.8
P/S
5
10.3
EV/S
6.9
7.5
EV/EBITDA
16
-1.6
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
19.7
131.1
Forward P/E
13.3
21.4
Dividend Yield, %
3.3
1.1
Forward Dividend Yield, %
3.5
0.1
Expected dividend per share
9.4
0
Payout Ratio, %
69.1
0
Dividend Ex Date
2024-05-16
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Biomarin Pharmaceutical Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
143240.4
Ticker
AMGN.O
ISIN
US0311621009
IPO date
1983-06-17
Availability on Russian exchanges
Yes
Reporting for
2024-02-14
Date fact. publication of reports
2023-12-31
Company Description
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: